Novozymes Biopharma, a Denmark-based provider of biomanufacturing, process development, drug formulation and drug delivery solutions, is set to unveil a new recombinant hyaluronic acid (HA) product for eye care and ophthalmic drug delivery.
Novozymes Biopharma claims the product offers optimal viscosity profiles for convenient application and increased patient comfort and compliance while superior heat stability permits autoclaving without loss of product viscosity.
The study results indicated that repeated applications of formulations containing HA onto the cornea do not induce corneal lesions.
In addition, the study demonstrates that Bacillus-derived HA offers superior stability during autoclaving when compared to a competitor product.
Novozymes Biopharma Global Marketing director Hans Ole Klingenberg said they are delighted to present the results of latest study into the use of HA in ophthalmology, which provides insight into the increasing need for a high purity HA ingredient for ophthalmic applications.
Novozymes Biopharma will showcase the product at the 2011 Joint Congress of the European Society of Ophthalmology (SOE) and American Academy of Ophthalmology (AAO), which will take place from 4-7 June 2011 in Geneva, Switzerland.
No comments:
Post a Comment